Author

C. B. Matsen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:organoid / primary culture· 1

Frequent Co-Authors

A. C. Beck· 1 shared A. Chakravarti· 1 shared A. J. Butterfield· 1 shared A. L. Welm· 1 shared A. R. Post· 1 shared A. S. Silva· 1 shared B. B. Morris· 1 shared B. E. Welm· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. C. Beck

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Replicative Instability Drives Cancer Progression

B. B. Morris, J. P. Smith, Q. Zhang, Z. Jiang, O. A. Hampton, M. L. Churchman, S. M. Arnold, D. H. Owen, J. E. Gray, P. M. Dillon, H. H. Soliman, D. G. Stover, H. Colman, A. Chakravarti, K. H. Shain, , M. W. Mayo

This study identifies a pan-cancer class of tumors driven by replicative instability, showing it accelerates cancer progression through genomic changes and transcriptional rewiring.

bioRxiv · May 6, 2022Cancer Biology

A breast cancer patient-derived xenograft and organoid platform for drug discovery and precision oncology

K. P. Guillen, M. Fujita, A. J. Butterfield, S. D. Scherer, M. H. Bailey, Z. Chu, Y. S. DeRose, L. Zhao, E. Cortes-Sanchez, C.-H. Yang, J. Toner, G. Wang, Y. Qiao, X. Huang, J. A. Greenland, , A. L. Welm

The paper develops patient-derived xenografts and organoids for breast cancer to enable drug screening and precision oncology, showing efficacy of an FDA-approved drug in a clinical case.

bioRxiv · Feb 28, 2021 · PreprintCancer Biology